IDH2 and cholangiocarcinoma: Approved molecular-directed drugs (FDA) for the treatment of advanced CCA in the palliative setting are FGFR inhibitors (pemigatinib, futibatinib, infigratinib), NTRK inhibitors (larotrectinib, entrectinib), the IDH inhibitor ivosidenib, and checkpoint inhibitors (pembrolizumab and durvalumab in combination with gemcitabine/cisplatin).